TMID - ETF AI Analysis
Top Page
T. Rowe Price Mid Cap Equity Research ETF (TMID)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Performing Top Holdings
Several of the largest positions, such as Phillips 66, TechnipFMC, Keysight Technologies, and Snowflake, have shown strong year-to-date performance, helping support the fund’s returns.
Broad Sector Diversification
The ETF spreads its investments across many sectors, including technology, industrials, financials, health care, energy, and real estate, which helps reduce the impact of weakness in any single industry.
Research-Driven Mid-Cap Focus
As a mid-cap equity research ETF, the fund targets medium-sized companies using T. Rowe Price’s research process, offering potential growth opportunities beyond large, more mature firms.
Negative Factors
Weak Overall Year-to-Date Performance
The ETF’s year-to-date performance has been slightly negative, indicating that the portfolio as a whole has lagged the broader market recently.
Underperforming Key Holding
Alnylam Pharma, one of the top holdings, has shown weak performance this year, which can drag on the fund’s overall results.
High U.S. Market Concentration
With nearly all assets invested in U.S. companies and very limited exposure to other countries, the fund is heavily tied to the direction of the U.S. market.
TMID vs. SPDR S&P 500 ETF (SPY)
AUM11.52M
RegionNorth America
Expense Ratio0.47%
Beta0.74
IssuerT. Rowe Price
Inception DateSep 16, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume785
30 Day Avg. Volume1,088
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
32.04Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering395
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMID Summary
TMID, the T. Rowe Price Mid Cap Equity Research ETF, focuses on medium‑sized U.S. companies across many industries instead of tracking a fixed index. It aims to find solid growth opportunities in the “middle tier” of the stock market using T. Rowe Price’s own research. The fund holds well-known names like Phillips 66 and Snowflake, along with many other mid-sized firms in technology, health care, energy, and more. Investors might consider TMID for diversified exposure to growing mid-sized companies, but should remember that its value can go up and down with the stock market.
How much will it cost me?This ETF has an expense ratio of 0.47%, which means you’ll pay about $4.70 per year for every $1,000 you invest. That’s higher than the average index ETF because TMID is actively managed, with professionals selecting and adjusting holdings rather than simply tracking a market index.
What would affect this ETF?TMID could benefit if the U.S. economy grows steadily, as its diversified mid-cap exposure across technology, industrials, financials, and health care may support company earnings, especially for holdings like software, energy, and medical firms. On the downside, higher interest rates, an economic slowdown, or sector-specific setbacks in areas like technology or health care could hurt mid-cap stocks more than larger, more established companies, and active management decisions that don’t work out as expected could also weigh on performance.
TMID Top 10 Holdings
TMID leans into innovative mid-cap names, with software players like Atlassian and Snowflake helping power recent gains as demand for cloud and data tools stays strong. Keysight Technologies has also been a steady contributor, riding solid fundamentals despite some valuation worries. On the flip side, Alnylam Pharma has been losing steam, weighing on health care exposure, while Modine and Element Solutions show more mixed, stop-and-go momentum in industrials and materials. Overall, the fund is firmly U.S.-focused, with a tilt toward tech and industrial growth stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Phillips 66 | 1.21% | $139.89K | $112.31B | 123.73% | 73 Outperform | |
| Alnylam Pharma | 1.17% | $134.85K | $30.38B | -52.31% | 60 Neutral | |
| Atlassian | 1.07% | $123.40K | $52.59B | 33.04% | 66 Neutral | |
| Element Solutions | 1.02% | $117.37K | $8.88B | 47.33% | 65 Neutral | |
| PTC | 1.00% | $115.47K | $21.12B | -4.01% | 73 Outperform | |
| Veralto Corporation | 0.94% | $107.73K | $23.94B | -2.94% | 76 Outperform | |
| Everpure | 0.92% | $105.61K | $51.75B | 69.70% | 64 Neutral | |
| Keysight Technologies | 0.88% | $100.85K | $64.30B | 124.59% | 77 Outperform | |
| TechnipFMC | 0.86% | $99.25K | $27.35B | 96.50% | 80 Outperform | |
| Liberty Media Corp. Series A Liberty Live | 0.85% | $98.03K | $8.87B | 11.62% | ― |
TMID Technical Analysis
Positive
―
Price Trends
Market Momentum
61.36
Neutral
94.01
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMID, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at 61.36 is Neutral, neither overbought nor oversold. The STOCH value of 94.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMID.
TMID Peer Comparison
Comparison Results
Performance Comparison
TMID
T. Rowe Price Mid Cap Equity Research ETF
25.62
0.53
2.11%
KMID
Virtus KAR Mid-Cap ETF
―
―
―
MMID
MFS Active Mid Cap ETF
―
―
―
SMCP
SMART Mid Cap ETF
―
―
―
MCDS
JPMorgan Fundamental Data Science Mid Core ETF
―
―
―
REMC
Columbia Research Enhanced Mid Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents